Who Paid My Doc
Blake Christensen
Interventional Pain Medicine Oklahoma City, OK Doctor of Osteopathy
NPI 1841425477 CMS profile 1279019
14000 N Portland Ave Ste 101, Oklahoma City, OK 73134
General payments
$5,750
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Blake Christensen of Oklahoma City, OK is reported in the CMS Open Payments database as having received $5,750 across 227 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 59th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $227 | 12 | |
| 2024 | General | $273 | 10 | |
| 2023 | General | $386 | 13 | |
| 2022 | General | $355 | 18 | |
| 2021 | General | $795 | 45 | |
| 2020 | General | $1,117 | 51 | |
| 2019 | General | $2,597 | 78 |
Beside peers
- Blake Christensen
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Blake Christensen were reported at $227. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Blake Christensen | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,597 | $684 | $216–$2,079 | $163 |
| 2020 | $1,117 | $382 | $122–$1,109 | $114 |
| 2021 | $795 | $552 | $167–$1,554 | $132 |
| 2022 | $355 | $605 | $187–$1,924 | $149 |
| 2023 | $386 | $671 | $195–$1,915 | $160 |
| 2024 | $273 | $684 | $206–$1,837 | $164 |
| 2025 | $227 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
3,418
Drug cost
$95,368
Branded share of claims
48.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 691 | $18,617 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 475 | $16,496 | |
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 92 | $13,710 | |
| Belbuca Buprenorphine Hcl | Brand | 18 | $12,368 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 379 | $8,267 | |
| Tramadol Hcl | Generic | 478 | $5,102 | |
| Gabapentin | Generic | 297 | $4,235 | |
| Buprenorphine Hcl | Generic | 91 | $3,530 | |
| Pregabalin | Generic | 245 | $3,357 | |
| Asa-Butalb-Caffeine-Codeine Codeine/Butalbital/Asa/Caffein | Brand | 16 | $1,673 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 62 billing codesPaid by Medicare
$1,302,192
Medicare patients
1,113
Services billed
19,571
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 35% | |
| Diabetes | 33% | |
| Depression | 31% | |
| Chronic kidney disease | 28% | |
| Osteoporosis | 24% | |
| COPD | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 740 | 2,512 | $13,684 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 411 | 8,489 | $766 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 722 | 2,453 | $712 |
| Injection, promethazine hcl, up to 50 mg J2550 | Office | 49 | 75 | $200 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 57 | 138 | $72 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
227 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Oklahoma
Brandon Valantine
Interventional Pain Medicine · Oklahoma City, OK
Amer Nouh
Interventional Pain Medicine · Edmond, OK
Muhammad Maqbool
Interventional Pain Medicine · Tulsa, OK
Justin Porter
Interventional Pain Medicine · Oklahoma City, OK
Samuel Korbe
Interventional Pain Medicine · Tulsa, OK
Joshua Woolard
Interventional Pain Medicine · Edmond, OK
Related records
Interventional Pain Medicine in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.